The FDA has approved the subcutaneous formulation of tocilizumab for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older, according to a press release ...

The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD. The Food and Drug Administration (FDA) has approved ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous ...

March 25, 2013 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku Tokyo; Chairman & CEO: Osamu Nagayama (hereafter, "Chugai")] announced today that the subcutaneous injection formulation ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved ACTPen, a single-dose prefilled autoinjector of tocilizumab, for the treatment of adult ...

ZURICH, July 19 (Reuters) - Roche's Japanese subsidiary Chugai said on Tuesday subcutaneous injection of its Actemra drug has shown efficacy in rheumatoid arthritis compared to intravenous infusion.

The efficacy of Actemra SC among pediatric patients (ages 2–17) was extrapolated from established data of Actemra IV in PJIA patients and of Actemra SC in patients with rheumatoid arthritis. For SC ...

ACTEMRA is shown to improve outcomes including mortality in patients hospitalized with COVID-19 requiring supplemental oxygen. 1 The authorization provides an additional option for hospitalized ...